Loss of proteostasis
Your cells run a constant quality-control operation on their own proteins — folding them correctly, and shredding the ones that come out wrong — and the machinery for this is thought to weaken with age, letting damaged proteins build up. It is one of the most elegant stories in aging biology and one of the least actionable: the evidence that it drives normal human aging is thinner than the confident textbook diagrams suggest, and outside of specific diseases there is no proven way to improve it.
Loss of proteostasis is the fourth of the twelve hallmarks of aging. "Proteostasis" is shorthand for protein homeostasis — keeping the cell's roughly ten thousand different proteins correctly folded, correctly located, and correctly disposed of when they wear out. A protein is a chain of amino acids that only works if it folds into a precise three-dimensional shape; a misfolded one is at best useless and at worst sticky, clumping together with others into aggregates the cell cannot clear. The failure of this system is the accepted explanation for Alzheimer's disease, Parkinson's disease, and the amyloidoses — diseases in which a normally soluble protein turns into deposits that accumulate in tissue.[1]
How confident should you be
Descriptive — Moderate. The machinery is real and its failure is well characterised in cultured cells. But the human evidence for a steady lifelong decline is thin: most of it is cells in a dish, the few human-tissue studies compare different people at different ages, the timing of the decline differs between tissues, and one animal study found no universal decline at all.
Intervention — none proven. Only one experiment we know of in normally aging mammals has claimed longer life from boosting protein quality control: a small mouse study that has never been repeated and whose untreated mice died young. When a large US government mouse-testing programme tried a protein-folding drug, it did not extend life. The drugs that genuinely repair a folding defect work only against a single named protein in a single defined disease. The two supplements sold for this that got proper trials both missed.
The three arms of quality control
The cell defends its proteins on several fronts at once, and the arms are worth separating because they fail — and are studied — differently.
Chaperones fold and refold. Molecular chaperones are proteins whose job is to shepherd other proteins into the right shape and rescue them when heat, oxidation, or crowding knocks them out of it. The best-known are the heat-shock proteins (HSP70, HSP90, and a family of small ones), so named because they surge when a cell is heated. Their master switch is HSF1, a protein that controls which genes get switched on; it sits dormant until stress activates it and then turns on the whole chaperone program.[2]
The proteasome shreds. Proteins that are too far gone to rescue get tagged with a small marker called ubiquitin and fed into the proteasome, a barrel-shaped molecular shredder that chops them back into amino acids. This is the ubiquitin-proteasome system, and it handles most of the cell's routine protein turnover.
The unfolded-protein response sounds the alarm. When misfolded proteins pile up inside the endoplasmic reticulum — the compartment where proteins destined for export are made — a set of sensors detects the backlog and throttles new protein production while boosting chaperone output, buying the cell time to catch up.[3]
A fourth arm, autophagy, digests aggregates and worn-out organelles wholesale. It is important enough, and separate enough, to have its own hallmark and its own page: see disabled macroautophagy. This article deals with the other three.
What actually declines in humans — and how thin the evidence is
Weak — mostly cell culture, with human-tissue data only now arriving. Here the honest answer is uncomfortable, and it is the reason this article is more cautious than most accounts you will read.
The cleanest study took skin fibroblasts from donors aged 20 to 82 and measured their proteasome activity. Capacity did fall with age — and the shortfall was real rather than merely an assay artefact, because oxidised and ubiquitin-tagged proteins piled up in exactly the cells whose shredders had slowed, which is what proteostasis failure is supposed to look like. But the decline was biphasic: it fell significantly up to about age 50, then showed no further significant change between 50 and 78.[4] Whatever you lose, on this evidence, you have largely lost by midlife — at least in cultured skin cells; the brain-tissue data below suggest the brain keeps changing well past 50. Worth knowing whose question this was answering: the work came from the research arm of a cosmetics company, and its stated conclusion is about delaying skin aging. That does not make it wrong — it remains the best human dataset available — but the field's anchor study was built around skin aging, not human aging in general.
The chaperone arm shows a similar pattern with a specific lesion. In senescent human fibroblasts — cells that have stopped dividing but refuse to die — the heat-shock response is broken at HSF1 itself: after a heat challenge, senescent cells got less than a third as much activated HSF1 into the nucleus, switched on a 161-gene stress program including 27 chaperones less strongly than young cells did, and lost 31% of their proteasome activity during the challenge — a deficit that deepened to 45% during what should have been the recovery period, while young cells were unaffected throughout. Notably, the cells could still sense the stress; what they had lost was the ability to mount a response to it.[5]
Now the caveats, which are load-bearing:
- Both findings are cultured cells, one of them fetal lung fibroblasts pushed into senescence by repeated division and then heated to 44 °C. That is not a 60-year-old's physiology, and it cannot tell you how much folding capacity you personally have lost.
- The decline is not universal. Aged rat brain retains normal capacity to degrade ubiquitin-tagged proteins — if anything slightly more — even as its ability to cut simpler test substrates falls.[6] And in female mice, proteasome activity changed in different directions in different tissues, leading the authors to conclude flatly that there is no universal decline in proteasome function with age.[7]
- Some of the longest-lived subjects hold on to their capacity. In that same mouse study, the exceptionally old animals had the best-maintained proteasome activity, not the worst. The same pattern appears in humans: fibroblasts from four healthy centenarians looked like those of young donors rather than elderly ones on every assay tried.[8] Four cell lines is not much to build on, but it is hard to square with a simple "it wears out" model.
So the flat claim "your proteostasis is failing with age" is not something the human data can support. What it supports is narrower: protein quality control can fail, it demonstrably does so in cultured aged and senescent cells, and the failure is real enough to leave a trail of undegraded protein behind it.
One caveat on that caveat. The "it's all cell culture" objection is beginning to weaken. A large 2025 atlas measured proteins in 516 samples from 13 human tissues, taken from people whose ages spanned five decades, and reported a broad decline in protein quality control, with amyloid-type deposits building up, and a turning point in tissue aging around age 50.[9] A preprint from the Buck Institute went further and measured the insoluble protein fraction directly in post-mortem brain tissue (the hippocampus, a memory centre) from 52 disease-free women aged 20 to 88 who were cognitively normal when they died. It found something more interesting than steady accumulation: the aggregate population remodels, starting in midlife. The most stable aggregates decline sharply in old age while intermediate-stability ones — the fraction enriched for Alzheimer's plaque and tangle constituents — build gradually and then accelerate after 80. Most relevant here, people of the same age differed widely in how much aggregate they carried, and the amount of proteasome and chaperone machinery in a given brain explained those differences about as well as age did, which ties the apparatus directly to the outcome it is supposed to control.[10] Hold on to the limits. Both studies compare different people at different ages rather than following anyone over time; the brain study is not yet peer-reviewed and included only women; and its timing differs from the fibroblast work, because the remodelling begins in midlife but most of the change comes later, with steep shifts between middle and old age and the sharpest rise after 80. These are measurements, not levers, and they complicate the naive picture of aggregates simply piling up rather than confirming it.
The species gap is the headline
Strong for lifespan in worms and flies; one weak, unreplicated lifespan result in mammals. The evidence that boosting proteostasis extends life is real and robust in invertebrates, and almost absent in mammals.
In the worm C. elegans, adding extra copies of the proteasome subunit rpn-6 is sufficient to make animals resistant to protein-folding stress and to extend their lifespan.[11] Overexpressing the chaperone master switch hsf-1 — the worm's spelling of the same HSF1 introduced above — extends lifespan too.[12] In fruit flies, switching on a proteasome subunit in adult neurons alone produced a robust extension of lifespan.[13]
That fly experiment also contains the most under-quoted result in this literature. The same paper switched the subunit on everywhere in the body rather than only in neurons — and lifespan did not budge, while some healthspan measures got worse. More protein quality control is not simply better; where it helped, it helped in one tissue, and generalising it did harm.
Then you cross into mammals, and the lifespan results all but stop.
Mice engineered to overexpress human HSF1 do get a better stress response — but the gain is almost entirely in the inducible reaction to a challenge, with baseline chaperone levels barely shifted, and no aging or lifespan endpoint was measured at all.[14] The most encouraging mammalian result is recent: aged mouse brain loses about 70% of its working shredder capacity in one proteasome form and half in the other, and boosting a proteasome subunit specifically in neurons slowed the age-related decline in spatial learning and memory in middle-aged and old mice — with no effect in the youngest group (already 12-month-old adults), exactly the age-restricted pattern you would predict if the deficit were what limited them. In the same paper, a short course of an experimental proteasome-activating compound improved memory-test performance in old mice but not young ones.[15] That is a genuine result. But the groups were small, the endpoint was cognition rather than lifespan, and it came from a single laboratory — the same laboratory that ran the fly experiment above. The fly step and the mouse step of the chain below share a senior author.
There is, as of now, no convincing mammalian experiment in which boosting proteostasis extended lifespan, and only one that claims to (a drug that switches part of the protein-stress alarm on did lengthen male lifespan in a government mouse-testing programme, but probably for an unrelated reason; see below). One research group gave old and middle-aged male mice a nasal spray of the human chaperone Hsp70 for the rest of their lives and reported median lifespan up by about 10–16%.[16] But the groups were small (25–34 mice each), the result has never been repeated, and the untreated mice died young, at a median of about 19–20 months. A well-run mouse lifespan study should see its control animals reach a median of roughly 30 months; when they die early, a treatment can look better than it is.[17] (In mice bred to develop Alzheimer's-like disease, boosting the proteasome does cut early deaths, but that is rescuing a disease, not slowing aging.[18])
Where lifespan has been measured in other ways, the results have been flat. Female mice engineered to make extra amounts of a proteasome-activating protein lived no longer than normal mice, though the extra protein actually lowered the proteasome capacity it was meant to raise, so this was a weak test.[19] The US government's multi-site mouse drug-testing programme fed mice 4-phenylbutyrate, a "chemical chaperone" that helps proteins fold; it did not extend life in either sex and slightly shortened it in females.[20] The same programme found no effect from 2BAct, a drug chosen because it switches off the cell's protein-stress alarm. Halofuginone, which switches part of that alarm on, lengthened median life in male mice by about 9% but not in females; its testers raise the possibility that it works by mimicking a diet low in certain amino acids, which says nothing about better protein quality control.[21]
So the chain of evidence runs: human cells decline in a dish → worms and flies live longer if you boost them, and in flies only in the right tissue → mice think better if you boost them → one small, unreplicated mouse lifespan result → and there it stops.
Two further complications deserve stating plainly. First, even in worms the mechanism is not what it appears: an engineered version of HSF-1 extended lifespan without enhancing chaperone induction at all, working instead through the cell's structural scaffolding.[22] So "more chaperones, longer life" is not established even in the animals where the lifespan effect is real. Second, HSF1 is not a free lunch — Caution: deleting it protects mice from tumours driven by mutations in RAS, one of the commonest cancer-causing genes, or by a frequent cancer mutation in p53, a gene that normally suppresses tumours, and human cancer cell lines turned out to depend on HSF1 much more than non-cancerous cells do, because malignant cells lean on the chaperone system to survive their own chaos.[23] Anything that durably cranks up HSF1 in a healthy adult is dialling a knob that cancers also like to see turned up.
The neurodegeneration trap
Moderate — the strongest-sounding argument for proteostasis, and the data resist it. Its failure is Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis — all diseases of a specific protein misfolding and clumping. If aggregation destroys brains, surely aggregation is destroying yours a little every year?
The data resist this move in two ways.
Aggregation is common, and often silent. Pooling 55 studies and nearly 3,000 people with entirely normal cognition, the prevalence of Alzheimer's-type amyloid in the brain rises from about 10% at age 50 to 44% by age 90.[24] Nearly half of cognitively normal ninety-year-olds are carrying the pathology while testing normal. That does not mean all of them are in the clear — the same paper infers a 20-to-30-year gap between becoming amyloid-positive and developing dementia, so some are early rather than exempt. But a lag that long is itself the point: aggregate burden and clinical disease are dissociable over decades, which is precisely what you would not expect if protein aggregation were a straightforward dose-dependent poison.
Clearing the aggregate barely helps the patient. This is the most instructive test the proteostasis hypothesis has been given, and it was run at enormous expense. Pooled across randomised trials, the anti-amyloid antibodies do what they were designed to do: they strip amyloid out of the brain, and by the standard yardstick for comparing effects measured on different scales, the effect is very large — a shift of more than one full standard deviation, which counts as large by any conventional reckoning. The effect on how patients actually are is a shift of 0.06 standard deviations on the primary measure, the Clinical Dementia Rating sum-of-boxes — an 18-point clinician-rated scale of dementia severity. That is far below the threshold at which a patient or clinician would notice anything. Even donanemab, the best performer, moved that scale by about 0.70 points against the 1-point bar for a noticeable difference. Meanwhile brain swelling became almost eight times more likely.[25] The 2026 Cochrane review, pooling 17 trials and more than 20,000 people with mild cognitive impairment or mild dementia, puts that in absolute terms: across the 11 trials (about 13,600 people) that reported it, about 107 more people per 1,000 treated showed swelling on scans; swelling that caused symptoms was rarer, about 29 more per 1,000, which the review rated as probably little or no difference, based on only 2 trials. It called the effect on thinking and dementia severity trivial, and concluded that removing amyloid "does not seem to be associated with clinically meaningful effects".[26]
Hold those two results side by side: the target moved enormously and the patient barely moved at all. You can read that charitably — and the authors do, as does the manufacturer, arguing that treating earlier and longer might let a small effect compound into a real one. The company's three-year donanemab follow-up reports a difference of about 1.2 points on the dementia scale, but measured against an outside comparison group drawn from a separate observational study, because the original placebo group had been switched onto the drug.[27] Other researchers replied that the data "do not robustly support" a changed course of disease.[28] The charitable reading is not unreasonable; it is simply not yet shown. But you cannot read it as a vindication. The cleanest test of "remove the misfolded protein, restore the function" came back with a resounding sort of, barely.
The one drug class that genuinely works — and what it does not prove
Strong, for one disease. There is a real proteostasis success story, and it is worth understanding precisely because of how narrow it is.
In transthyretin amyloid cardiomyopathy, a blood protein called transthyretin misfolds and deposits in heart muscle, stiffening it. Tafamidis is a small molecule that clamps transthyretin into its correct shape so it cannot misfold in the first place — proteostasis repair in its purest available form. In a 441-patient randomised trial over 30 months, it cut deaths from any cause from 42.9% to 29.5% — about 13 fewer deaths per 100 patients treated, or roughly 30% lower risk (hazard ratio 0.70, 95% CI 0.51–0.96). That bracketed range is where the true effect most plausibly lies; when such a range crosses 1.0 the result is compatible with no effect at all, and when it sits entirely below 1.0, as here, the benefit is unlikely to be chance. The drug also reduced cardiovascular hospitalisations from 0.70 to 0.48 per year and slowed the decline in both walking distance and quality of life.[29]
The principle has since held up twice more, which matters, because a single trial of a single molecule would be a thin foundation. Acoramidis, a second stabiliser working the same way, beat placebo in 632 patients on a combined ranking of death, hospitalisation and function over 30 months — not on mortality specifically.[30] When the placebo group was then switched onto the drug, patients who had started it from the beginning had about 45% lower risk of death by four and a half years (hazard ratio 0.55); that compares early with delayed treatment rather than drug with no drug, and the later years were unblinded.[31] And vutrisiran attacks the problem from the other end: instead of fixing the fold, it shuts down production of the protein, cutting deaths from any cause over 42 months by about 35% (hazard ratio 0.65, 95% CI 0.46–0.90).[32] All three trials were funded by the companies selling the drugs, which is normal for cardiology and worth knowing anyway.
That is a large mortality benefit from stabilising a misfolding protein, and the principle has held in three trials of two strategies. It has not held everywhere: in the largest trial yet, 1,432 patients were randomised to a second silencing drug, eplontersen, or placebo, and the drug did no better on cardiovascular deaths and heart events overall (rate ratio 0.89, with a 95% range of 0.73–1.09 that includes no effect).[33] A planned breakdown hints at why: the silencer helped patients who were not already taking a stabiliser (about 29% fewer events, rate ratio 0.71) and showed no benefit in the 57% who were.[34] A subgroup from a trial that missed its main goal is a hint, not a finding. The three successful trials prove the principle — and they also show exactly what the principle requires. These drugs work because there is one culprit protein, with a known misfolding mechanism, causing a specific disease, in patients selected because they have it. None of those conditions holds for ordinary aging, where the hypothesised problem is a diffuse, gradual loss of general folding capacity with no single protein to stabilise and no drug that could stabilise all of them at once. Note that even the silencer, which sidesteps folding entirely, needs the same thing the stabilisers do: a named protein to remove. This drug class validates proteostasis as a target for a defined proteinopathy. It says nothing about whether a healthy 50-year-old should be trying to boost their chaperones.
The heart is now getting its own version of the Alzheimer's test: antibodies designed to clear existing transthyretin deposits out of the muscle rather than prevent new ones. In a 104-patient randomised trial, most of whom were already on tafamidis, the higher dose of one such antibody, coramitug, cut a blood marker of heart strain by about half compared with placebo over a year. It did not improve how far patients could walk compared with placebo.[35] Whether clearing the deposit helps patients live longer or stay out of hospital has not yet been shown.
What you can actually do (very little, honestly)
Sauna — Weak; the mechanism is weaker than advertised. The logic runs: heat induces heat-shock proteins, heat-shock proteins are chaperones, therefore sauna improves proteostasis. The human data supporting the first link are thin and inconsistent. The most-cited study is not a sauna study at all: 25 healthy university-age adults sat in a heat chamber at 73 °C for 30 minutes, and in the 13 who gave blood samples, a circulating heat-shock protein (HSP72, from the HSP70 family) rose by 48.7% — but with a standard deviation of ±53.9%, meaning the variation between individuals exceeded the average effect.[36] What rises in the blood is extracellular heat-shock protein, which acts as a stress and immune signal; it is not evidence that the chaperones inside your cells are folding proteins better. Studies that took muscle samples get closer, and disagree. Heating one thigh with deep-tissue diathermy for 2 hours a day over 6 days raised muscle HSP70 by about 45% and HSP90 by about 38% in 20 adults.[37] But in 7 active young men, an hour of soaking one leg in hot water raised none of the chaperones measured,[38] and in 7 young adults, 3 hours of leg heating raised the genetic instructions for HSP72 without raising the protein itself.[39] A 2025 meta-analysis pooling blood and tissue measurements found no significant change in heat-shock proteins after either single or repeated heat sessions, though it had few studies to work with.[40] None of the muscle studies was a sauna, and none of these studies measured whether proteins actually fold better. The bridge from "heat raises a chaperone marker" to "sauna improves your protein quality control" is, at present, an inference and not a finding.
None of which means don't use the sauna. It means use it for the reasons that actually have outcome data behind them — see sauna — and not because you are tuning your proteostasis.
The supplements aimed at this have missed — Weak. Spermidine got the trial the field wanted: 100 older adults with subjective cognitive decline, 12 months, randomised and placebo-controlled. It did not improve memory, and it did not move the biomarkers.[41] One honest caveat on the strength of that null: the dose was 0.9 mg per day of a wheat-germ extract, and the authors themselves call for trials at higher doses. Urolithin A is often marketed in this space, though its mechanism is really mitochondrial recycling rather than protein folding; in 66 older adults it failed both of its primary endpoints, and the muscle-endurance benefit that did appear at 2 months had evaporated by 4 months as the placebo group caught up. That trial was run with the manufacturer's involvement, so the null is if anything the conservative reading.[42] Newer small trials of both have moved immune markers but not clinical outcomes, and a 2026 urolithin A trial found no improvement in blood-vessel function.[43] None of them measured protein quality control directly. Both supplements are covered further under geroprotectors.
Drugs that boost chaperones directly have failed too — Weak. Arimoclomol turns up the cell's heat-shock response, so it is the closest thing to a "chaperone booster" tested in people. In 152 patients with inclusion body myositis, a muscle disease marked by clumped protein, 20 months on the drug did not slow the loss of function compared with placebo, and more people stopped because of side effects (18% vs 5%).[44] In 239 patients with early ALS, it did no better than placebo on a combined score of function and survival over 76 weeks, and more people quit because of side effects (16% vs 5%); the authors add that a higher dose would not have been tolerated.[45] If boosting chaperones does not help in diseases defined by misfolded protein, there is little reason to expect it to help a healthy person.
You cannot measure it — Caution on anyone who offers to. There is no validated blood test of "proteostasis capacity." The aggregation-related blood markers that do exist and work well are diagnostic tools for people who already have symptoms. The best of them, p-tau217 and p-tau181 (fragments of the tau protein that tangles inside neurons) and the amyloid-beta 42/40 ratio, are covered by the 2025 Alzheimer's Association clinical practice guideline, which restricts them to patients with objective cognitive impairment in specialist care and states explicitly that it "does not extend to cognitively unimpaired individuals, given the current lack of clinical relevance."[46] The same guideline warns that many commercially available versions of these tests do not meet its accuracy thresholds. Two other markers often measured alongside them, neurofilament light (released when nerve fibres are damaged) and glial fibrillary acidic protein (released when the brain's support cells react to injury), were left out of the guideline altogether, so there is no guideline-backed reason to order them as a check-up either. If you are well and someone offers to measure your amyloid biology, the profession's own guideline says there is no established reason to.
What this does and doesn't tell you
What it tells you: protein quality control is real machinery, it demonstrably fails in aged and senescent human cells, and repairing a specific folding defect can save lives — the transthyretin drugs are proof, in three successful trials (a fourth, larger one missed). The mechanism deserves its place among the hallmarks.
What it doesn't tell you: that your proteostasis is measurably declining (the human data are mostly cell culture plus recent snapshots of tissue from people of different ages, and they disagree on timing: skin cells plateau after 50, while brain tissue changes most between late middle age and old age, with the sharpest rise after 80); that boosting it would extend a mammal's life (the one mouse study claiming longer life is small, unreplicated and used short-lived controls, a protein-folding drug did nothing in a large mouse-testing programme, and the fly experiment that boosted it body-wide made things slightly worse); that clearing aggregated protein reliably restores function (the antibody trials moved the target enormously and the patients barely at all); or that any available supplement, sauna protocol, or blood test lets you act on it. The honest position is that this is the hallmark with the widest gap between the beauty of the mechanism and the emptiness of the shelf — and the correct response to an empty shelf is to notice that it is empty, not to buy something anyway.
There is no proteostasis-specific lever worth naming. The general ones — exercise, sleep, staying metabolically uninflamed — are the best available bet, and the deep-sleep brain-clearance story is often invoked here, but for sleep and metabolism that is inference from what those habits do elsewhere in the body. For exercise there is one small direct hint: in a trial of 38 older adults, muscle samples showed about 35% more of the stress chaperone HSP70 than in young adults who had not been training, and 12 weeks of strength training brought it down by roughly 30%, suggesting less cellular stress.[47] That is a change in a marker, not proof that proteins are handled better. Do those habits for the reasons that have outcome data. See genomic instability for the same argument in a different hallmark, and dementia prevention for what is genuinely known about protecting the aging brain.
Further reading
- Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol 2019.[48]
- López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023.[49]
- Hwang JS, et al. Age-associated decrease in proteasome content and activities in human dermal fibroblasts: restoration of normal level of proteasome subunits reduces aging markers in fibroblasts from elderly persons. J Gerontol A Biol Sci Med Sci 2007.[50]
- Sabath N, et al. Cellular proteostasis decline in human senescence. Proc Natl Acad Sci U S A 2020.[51]
- Martínez de Toda I, et al. Female mice reaching exceptionally high old age have preserved 20S proteasome activities. Antioxidants (Basel) 2021 — mouse study.[52]
- Chondrogianni N, et al. Fibroblast cultures from healthy centenarians have an active proteasome. Exp Gerontol 2000 — cell lines from four centenarians.[53]
- Vilchez D, et al. RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature 2012 — worm study.[54]
- Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 2003 — worm study.[55]
- Munkácsy E, et al. Neuronal-specific proteasome augmentation via Prosβ5 overexpression extends lifespan and reduces age-related cognitive decline. Aging Cell 2019 — fly study.[56]
- Parker D, et al. Proteasome augmentation mitigates age-related cognitive decline in mice. Aging Cell 2025 — mouse study.[57]
- Baird NA, et al. HSF-1-mediated cytoskeletal integrity determines thermotolerance and life span. Science 2014 — worm study.[58]
- Dai C, et al. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007.[59]
- Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018 — ATTR-ACT trial.[60]
- Gillmore JD, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024 — ATTRibute-CM trial.[61]
- Fontana M, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 2025 — HELIOS-B trial.[62]
- Avgerinos KI, et al. Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness. Sci Rep 2024.[63]
- Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015.[64]
- Schwarz C, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: a randomized clinical trial. JAMA Netw Open 2022 — SmartAge trial.[65]
- Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Netw Open 2022.[66]
- Iguchi M, et al. Heat stress and cardiovascular, hormonal, and heat shock proteins in humans. J Athl Train 2012 — heat chamber, not sauna; blood samples from 13 people.[67]
- Palmqvist S, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement 2025.[68]
- Anderton E, et al. Shifts in protein aggregate stability define proteostasis decline in the aging human brain. bioRxiv 2026 — preprint, not peer-reviewed.[69]
- Bobkova NV, et al. Exogenous Hsp70 delays senescence and improves cognitive function in aging mice. Proc Natl Acad Sci U S A 2015 — mouse study, unreplicated.[70]
- Pabis K, et al. The impact of short-lived controls on the interpretation of lifespan experiments and progress in geroscience - Through the lens of the "900-day rule". Ageing Res Rev 2024.[71]
- Chocron ES, et al. Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer's-like pathology in mouse and fly APP overexpression models. Sci Adv 2022 — Alzheimer's-model mice and flies.[72]
- Adelöf J, et al. PA28α overexpressing female mice maintain exploratory behavior and capacity to prevent protein aggregation in hippocampus as they age. Aging Cell 2021 — mouse study.[73]
- Harrison DE, et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. Geroscience 2024 — NIA Interventions Testing Program.[74]
- Strong R, et al. Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice. Geroscience 2026 — NIA Interventions Testing Program.[75]
- Ding Y, et al. Comprehensive human proteome profiles across a 50-year lifespan reveal aging trajectories and signatures. Cell 2025.[76]
- Hafen PS, et al. Repeated exposure to heat stress induces mitochondrial adaptation in human skeletal muscle. J Appl Physiol (1985) 2018 — muscle biopsies.[77]
- Morton JP, et al. Elevated core and muscle temperature to levels comparable to exercise do not increase heat shock protein content of skeletal muscle of physically active men. Acta Physiol (Oxf) 2007 — muscle biopsies.[78]
- Gibson OR, et al. Skeletal muscle angiogenic, regulatory, and heat shock protein responses to prolonged passive hyperthermia of the human lower limb. Am J Physiol Regul Integr Comp Physiol 2023 — muscle biopsies.[79]
- Price BS, et al. Heat thermotherapy to improve cardiovascular function and cardiometabolic health: A systematic review and meta-analysis. Exp Physiol 2025.[80]
- Soman P, et al. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol 2026 — ATTRibute-CM open-label extension.[81]
- Fontana M, et al. Eplontersen for Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2026 — CARDIO-TTRansform trial.[82]
- García-Pavía P, et al. Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial. Nat Med 2026 — secondary analysis of CARDIO-TTRansform.[83]
- Nonino F, et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2026.[84]
- Zimmer JA, et al. Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. J Prev Alzheimers Dis 2026 — TRAILBLAZER-ALZ 2 extension.[85]
- Hazan J, Liu KY, Howard R. Long-term extension data do not robustly support clinical disease course modification with donanemab. J Prev Alzheimers Dis 2026 — letter.[86]
- Fontana M, et al. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation 2026 — phase 2 trial.[87]
- Machado PM, et al. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2023.[88]
- Benatar M, et al. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol 2024 — ORARIALS-01 trial.[89]
- Denk D, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nat Aging 2025 — manufacturer-funded.[90]
- Alsaleh G, et al. Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot Study. Aging Cell 2026 — pilot study.[91]
- da Costa Pinaffi-Langley AC, et al. Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity: A Randomized Clinical Trial. JAMA Netw Open 2026.[92]
- Cumming KT, et al. Muscular HSP70 content is higher in elderly compared to young, but is normalized after 12 weeks of strength training. Eur J Appl Physiol 2021.[93]